Neurocrine registers Phase 1/2 gene therapy trial for Friedreich's AtaxiaNov 12Trial updateNeurocrine Biosciences
Neurocrine posts $1.1 billion quarter, raises INGREZZA sales guidanceNov 2Quarterly updateNeurocrine Biosciencesvalbenazine
Neurocrine Biosciences: INGREZZA (NDA209241) SUPPL 34 approvedOct 23Regulatory decisionNeurocrine BiosciencesvalbenazineRecord notice
Neurocrine registers Phase 2 trial of NBIP-01435 in classic congenital adrenal hyperplasiaSep 30Trial updateNeurocrine Biosciences
Neurocrine names Eiry Roberts chief medical officer, replacing Sanjay KeswaniSep 28PeopleNeurocrine Biosciences
Neurocrine registers Phase 2a trial of NBI-1117567 in mild to moderate Alzheimer's diseaseSep 22Trial updateNBI-1117567Neurocrine Biosciences
Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readoutsJul 30Quarterly updateNeurocrine Biosciencesvalbenazine